FDA BRIEF: Week of June 12, 2017

FDA approved

SYMJEPI (epinephrine injection)

Adamis Pharmaceuticals Corporation


Emergency treatment of allergic reactions (Type I) including anaphylaxis  to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.

For immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema.

For immediate administration as emergency supportive therapy only and is not a
substitute for immediate medical care.

ADDRESSING UNMET NEED: New drug alternative to EpiPen


  • 505(b)(2) pathway
  • Postmarketing Commitment: Fault Tree Analysis and quantification to support device reliability specification

MECHANISM OF ACTION: Acts on both alpha and beta-adrenergic receptors

EFFICACY & SAFETY: Established based on initial approval in 1939


Image credit: Adamis

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo

You are commenting using your Google account.
Log Out / 
Change )

Twitter picture

You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo

You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s